Back to Search
Start Over
Early response to Tezepelumab in type-2 severe asthma patients non-responders to other biological treatments: a real-life study.
- Source :
-
The Journal of asthma : official journal of the Association for the Care of Asthma [J Asthma] 2024 Oct; Vol. 61 (10), pp. 1347-1350. Date of Electronic Publication: 2024 May 09. - Publication Year :
- 2024
-
Abstract
- Background: Biologic therapies play a crucial role in the treatment of severe asthma. Tezepelumab, a human monoclonal antibody (mAb), inhibits thymic stromal lymphopoietin, a pivotal factor in the pathophysiology of asthma. Although randomized clinical trials have demonstrated the efficacy of Tezepelumab, evidence gaps remain in real-world scenarios.<br />Objective: We sought investigate Tezepelumab's response in a clinical setting, focusing on patients who previously failed to other asthma mAbs.<br />Methods: Real-life study with severe uncontrolled asthma patients despite mAb treatment, requiring a switch to Tezepelumab. Follow-up was done four to six months after initiation of Tezepelumab. The primary endpoint was to evaluate the response in patients with poor response or intolerance to other mAbs.<br />Results: Nine patients were followed up during 7 months. Patients were predominantly middle-aged females with eosinophilic or eosinophilic-allergic phenotypes. Patients had a median failure rate of 2 mAbs (IQR 2-3), with an uncontrolled asthma (median of 2 severe exacerbations the previous year, airflow obstruction and 78% corticosteroid dependence). Tezepelumab demonstrated after 4 to 6 months of treatment reduce corticosteroid dependence (complete withdrawal in 2/7 patients), no exacerbations in 6/9, symptoms control improvement (Asthma Control Test score improved in 5/9) and modulate lung function (improving in 3/9 patients). These findings align with clinical trial results, suggesting Tezepelumab's potential in real-world settings.<br />Conclusion: In real-world scenarios, despite the study's limitations, our results underscore Tezepelumab's promise as a therapeutic option for uncontrolled severe asthma, and may be useful for non-responders to other mAbs. Further studies are needed to corroborate these findings.
- Subjects :
- Humans
Female
Male
Middle Aged
Adult
Severity of Illness Index
Treatment Outcome
Aged
Antibodies, Monoclonal therapeutic use
Antibodies, Monoclonal administration & dosage
Asthma drug therapy
Asthma immunology
Antibodies, Monoclonal, Humanized therapeutic use
Anti-Asthmatic Agents therapeutic use
Anti-Asthmatic Agents administration & dosage
Subjects
Details
- Language :
- English
- ISSN :
- 1532-4303
- Volume :
- 61
- Issue :
- 10
- Database :
- MEDLINE
- Journal :
- The Journal of asthma : official journal of the Association for the Care of Asthma
- Publication Type :
- Academic Journal
- Accession number :
- 38686823
- Full Text :
- https://doi.org/10.1080/02770903.2024.2349605